Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Adding cognitive-behavioral therapy to serotonin reuptake inhibitors (SRIs) to treat obsessive-compulsive disorder (OCD) was superior in reducing symptoms compared with adding an antipsychotic drug or placebo (Simpson HB et al. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2013.1932 [published online September 11, 2013]).
Researchers randomized 100 adult patients with OCD, all of whom were taking SRIs, to receive 8 weeks of risperidone, 17 twice-weekly sessions of exposure and ritual prevention (EX/RP) cognitive-behavioral therapy, or placebo pills. More participants in the therapy group achieved minimal symptoms—42.5%, vs 12.5% for risperidone and 5% for placebo—as well as improved insight, functions, and quality of life. Risperidone was not significantly better than placebo on any outcome.
Slomski A. Adding Cognitive-Behavioral Therapy to SRIs May Improve OCD Symptoms . JAMA. 2013;310(16):1665. doi:10.1001/jama.2013.281198